Inhibition of hiv-1 replication by isoxazolidine and isoxazole sulfonamides

Chemical Biology and Drug Design

Volumn 75, Issue 5, 2010, Pages 461-474

  Loh, Belinda ^a   Vozzolo, Luciano ^a   Mok, B James ^b   Lee, Chien Chi ^b   Fitzmaurice, Richard J ^b   Caddick, Stephen ^b   Fassati, Ariberto ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene expression; HIV 1; Novel chemical entity; Sulfonamides

Indexed keywords

2 METHYL N (4 METHYLBENZYL) 3 PHENYL 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (2 BROMOPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (2 BROMOPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (2 CHLOROPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (2 CHLOROPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (2 FLUOROPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (2 FLUOROPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (2 IODOPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (2 IODOPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (3 BROMOPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (3 CHLOROPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (4 BROMOPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (4 BROMOPHENYL) N (4 METHYLBENZYL) 1,2 OXAZOLE 5 SULFONAMIDE; 3 (4 CHLOROPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (4 FLUOROPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (4 IODOPHENYL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; 3 (5 BROMOFURAN 2 YL) 2 METHYL N (4 METHYLBENZYL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ISOXAZOLE DERIVATIVE; ISOXAZOLE SULFONAMIDE DERIVATIVE; ISOXAZOLIDINE DERIVATIVE; N (2 HYDROXYETHYL) 2 METHYL 3 (NAPHTHALEN 2 YL) 1,2 OXAZOLIDINE 4 SULFONAMIDE; N (2 HYDROXYETHYL) 2 METHYL 3 PHENYL 1,2 OXAZOLIDINE 4 SULFONAMIDE; N TERT BUTYL 3 (3 CHLOROPHENYL) 2 METHYL 1,2 OXAZOLIDINE 4 SULFONAMIDE; N TERT BUTYL 3 (4 CHLOROPHENYL) 2 METHYL 1,2 OXAZOLIDINE 4 SULFONAMIDE; N TERT BUTYL 3 (4 METHOXYPHENYL) 2 METHYL 1,2 OXAZOLIDINE 4 SULFONAMIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; VIRUS ACTIVATION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG RESISTANCE, VIRAL; HELA CELLS; HIV-1; HUMANS; ISOXAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77949985878     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00956.x     Document Type: Article

References (33)

1. Palella F.J. Jr., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 : 853 860.
2. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellman N.S., Richman D.D. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 : 385 394.
3. Shafer R.W., Schapiro J.M. (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10 : 67 84.
4. Cane P., Chrystie I., Dunn D., Evans B., Geretti A.M., Green H., Phillips A. et al. (2005) Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331 : 1368.
5. Hue S., Gifford R.J., Dunn D., Fernhill E., Pillay D. (2009) Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 83 : 2645 2654.
6. Kellam P. (2006) Attacking pathogens through their hosts. Genome Biol 7 : 201.
7. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J. et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 : 4721 4732.
8. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S. et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11 : 1170 1172.
9. Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., Elledge S.J. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 : 921 926.
10. Konig R., Zhou Y., Elleder D., Diamond T.L., Bonamy G.M., Irelan J.T., Chiang C.Y. et al. (2008) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135 : 49 60.
11. Zhou H., Xu M., Huang Q., Gates A.T., Zhang X.D., Castle J.C., Stec E., Ferrer M., Strulovici B., Hazuda D.J., Espeseth A.S. (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4 : 495 504.
12. Stockwell B.R. (2004) Exploring biology with small organic molecules. Nature 432 : 846 854.
13. Terstappen G.C., Schlupen C., Raggiaschi R., Gaviraghi G. (2007) Target deconvolution strategies in drug discovery. Nat Rev 6 : 891 903.
14. Caddick S., Bush H.D. (2003) Synthesis of functionalized sulfonamides via 1,3-dipolar cycloaddition of pentafluorophenyl vinylsulfonate. Org Lett 5 : 2489 2492.
15. Lee C.C., Fitzmaurice R.J., Caddick S. (2009) 3,5-Isoxazoles from alpha-bromo-pentafluorophenyl vinylsulfonates: synthesis of sulfonates and sulfonamides. Org Biomol Chem 7 : 4349 4351.
16. Demaison C., Parsley K., Brouns G., Scherr M., Battmer K., Kinnon C., Grez M., Thrasher A.J. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13 : 803 813.
17. Fassati A., Goff S.P. (2001) Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 75 : 3626 3635.
18. Cutino-Moguel T., Fassati A. (2006) A phenotypic recessive, post-entry block in rabbit cells that results in aberrant trafficking of HIV-1. Traffic 7 : 978 992.
19. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59 : 284 291.
20. Clapham P.R., McKnight A., Weiss R.A. (1992) Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol 66 : 3531 3537.
21. Zaitseva L., Cherepanov P., Leyens L., Wilson S.J., Rasaiyaah J., Fassati A. (2009) HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. Retrovirology 6 : 11.
22. Ikegami S., Taguchi T., Ohashi M., Oguro M., Nagano H., Mano Y. (1978) Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha. Nature 275 : 458 460.
23. Goff S.P. (2004) Genetic control of retrovirus susceptibility in mammalian cells. Annu Rev Genet 38 : 61 85.
24. Fields B.N., Knipe D.M., Howley P.M. (2007) Fields' Virology, 5th edn. Philadelphia : Lippincott Williams & Wilkins.
25. Butler S.L., Johnson E.P., Bushman F.D. (2002) Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 76 : 3739 3747.
26. Bruce J.W., Ahlquist P., Young J.A. (2008) The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment. PLoS pathogens 4 : e1000207.
27. Hazuda D., Iwamoto M., Wenning L. (2009) Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 49 : 377 394.
28. Daelemans D., De Clercq E., Vandamme A.M. (2001) A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. J Virol Methods 96 : 183 188.
29. Yamashita M., Emerman M. (2004) Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol 78 : 5670 5678.
30. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.K., et al. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250 : 1411 1413.
31. Verdin E., Paras P. Jr., Van Lint C. (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 12 : 3249 3259.
32. Stevens M., De Clercq E., Balzarini J. (2006) The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev 26 : 595 625.
33. Van Lint C., Emiliani S., Ott M., Verdin E. (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15 : 1112 1120.